Bringing genetic testing into routine care across Indiana
Implementing a genomics-enabled Learning Health System across Indiana
['FUNDING_U01'] · INDIANA UNIVERSITY INDIANAPOLIS · NIH-11196183
This project introduces genetic testing for a chemotherapy-related gene (DPYD) and a kidney-risk gene (APOL1) to help people receiving fluoropyrimidine chemotherapy and people of African ancestry manage treatment risks and kidney health.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INDIANA UNIVERSITY INDIANAPOLIS (nih funded) |
| Locations | 1 site (INDIANAPOLIS, UNITED STATES) |
| Trial ID | NIH-11196183 on ClinicalTrials.gov |
What this research studies
From your perspective, the health system will roll out genetics tools across participating Indiana clinics and clinics will start using them at different times so patients can be compared before and after the change. One effort offers DPYD testing to people getting fluoropyrimidine chemotherapy so doctors can adjust doses and reduce severe drug side effects. The other offers APOL1 testing for patients, particularly those of African ancestry, to guide conversations and decisions about kidney disease risk and prevention. The project uses a learning health system approach to share what works, run pragmatic stepped-wedge trials, and spread useful tools across the network.
Who could benefit from this research
Good fit: Ideal candidates include people about to receive fluoropyrimidine chemotherapy and patients, especially those of African ancestry, who are being seen for kidney disease risk or management at participating clinics.
Not a fit: People who are not receiving fluoropyrimidine drugs and those without APOL1 risk concerns or who do not receive care at participating sites may not directly benefit from these interventions.
Why it matters
Potential benefit: If successful, this could lower severe chemotherapy toxicities and help identify and manage kidney disease risk for patients who carry APOL1 risk variants.
How similar studies have performed: DPYD-guided dosing has reduced severe fluoropyrimidine toxicities in other countries and clinical settings, while APOL1 testing is a newer approach with growing but still limited implementation evidence.
Where this research is happening
INDIANAPOLIS, UNITED STATES
- INDIANA UNIVERSITY INDIANAPOLIS — INDIANAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SKAAR, TODD C. — INDIANA UNIVERSITY INDIANAPOLIS
- Study coordinator: SKAAR, TODD C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.